Onco Wiki / Biomarker

EBV-Status (EBER-ISH auf Tumorgewebe)

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDBIO-EBV-STATUS
ArtBiomarker
Aliase
EBEREBVEBV-StatusEBV статус (EBER-ISH на тканині)Epstein-Barr-Virus
Statusreviewed 2026-04-25 | pending_clinical_signoff
ErkrankungenDIS-AITL DIS-GASTRIC
QuellenSRC-NCCN-BCELL-2025

Biomarker-Fakten

Biomarker-Typviral_load
Messung
VerfahrenEBER (EBV-kodierte RNA) in-situ Hybridisierung auf FFPE Gewebe. Serum EBV-DNA quantitativ für systemische Beteiligung
Einheitencategorical (positive | negative); EBV-DNA copies/mL for serum
Verwandte BiomarkerNone declared

Anmerkungen

Cross-disease etiologic + therapeutic significance: - **Endemic Burkitt** (equatorial Africa): EBV+ in ~95% - **Sporadic Burkitt** (Western): EBV+ in ~15% - **Classical Hodgkin**: EBV+ in ~30-40% (mixed cellularity highest) - **Post-transplant LPD (PTLD)**: EBV-driven; rituximab + reduce immunosuppression often curative - **HIV-associated DLBCL / plasmablastic / primary effusion**: EBV+ common - **NK/T nasal-type lymphoma**: EBV+ universally - **AITL microenvironment**: EBV+ B-cells frequent - **EBV+ DLBCL of elderly** (WHO 5th-ed entity): defined by EBV+ Drives different treatment context: - PTLD → reduce immunosuppression + rituximab - HIV-associated → cART + standard regimen - EBV+ HL has same regimen but PD-1 blockade emerging response differential Currently informational in our KB; not algorithm-driving for treatment selection but documented for clinical context.

Verwendet von

Therapeutische Relevanz

Biomarker

Warnhinweis